ArticleNature immunology2021
Proinflammatory IgG Fc structures in patients with severe COVID-19.
Abstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 234 papers.
0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
234 citing papers in PubMed.
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy.Cell reports. Medicine · 2022Trial
- Article
- Article
- Longitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients.Viruses · 2026Article
- Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.Scientific reports · 2026Article
- Post-Acute Sequelae of COVID-19 Across 15 Major Health Domains and 67 Diseases in Individuals With Depressive Disorder: A Korean Nationwide Cohort Study.Journal of Korean medical science · 2026Article
- Glycosylation profile ofiScience · 2026Article
- Characterization of IgG N-glycan patterns in COVID-19, sepsis and healthy subjects.Scientific reports · 2026Article
- Antibody repertoire associated with clinically diverse presentations of pediatric SARS-CoV-2 infection.Scientific reports · 2026Article
- Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodies.JCI insight · 2026Article
- Atypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity.Nature communications · 2026Article
- The association between plasma IgG N-glycosylation and viral encephalitis in children: a hospital-based case-control study.Italian journal of pediatrics · 2026Article
- Antigen-specific IgG glycosylation profiles in hamsters and macaques following COVID-19 vaccination.iScience · 2026Article
- Building better antibody responses: The interplay of infection, vaccination, and immune imprinting.PNAS nexus · 2026Review
- SARS-CoV-2 Anti-Spike IgG Subclass Titres in a Population with Prior Exposure to Perfluorooctanoic Acid (PFOA).Toxics · 2026Article
- Early Fc-effector antibody signatures impact COVID-19 disease trajectory.medRxiv : the preprint server for health sciences · 2026Article
- Longitudinal clinical proteomics reveals pneumonia type-specific protein biomarkers and autoantibodies.medRxiv : the preprint server for health sciences · 2026Article
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
- Immunoglobulin G in aging and cancer.Frontiers in immunology · 2026Review
- Fc-mediated antibody functions are associated with disease severity in COVID-19.Frontiers in immunology · 2026Article
174 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
27 authors.
Saborni ChakrabortyDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0502-3757
Joseph Gonzalez *Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Karlie Edwards *Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Vamsee MallajosyulaInstitute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA.
Anthony S BuzzancoDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Robert SherwoodProteomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY, USA.
Cindy BuffoneDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Nimish KathaleDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Susan ProvidenzaDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Markus M XieDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1350-7364
Jason R AndrewsDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5967-251X
Catherine A BlishDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6946-7627
Upinder SinghDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Haley DuganDepartment of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL, USA.
Patrick C WilsonDepartment of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-3537-1245
Tho D PhamStanford Blood Center, Palo Alto, CA, USA.
Scott D BoydDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0963-044X
Kari C NadeauSean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2146-2955
Benjamin A PinskyDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8751-4810
Sheng ZhangProteomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY, USA.ORCID http://orcid.org/0000-0001-8206-1007
Matthew J MemoliLID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jeffery K TaubenbergerLID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-9694-7228
Tasha MoralesTPMG Regional Reference Laboratory, Kaiser Permanente Northern California, Berkeley, CA, USA.
Jeffrey M SchapiroTPMG Regional Reference Laboratory, Kaiser Permanente Northern California, Berkeley, CA, USA.
Gene S TanJ. Craig Venter Institute, La Jolla, CA, USA.
Prasanna JagannathanDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA.
Taia T WangDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA. taiawang@stanford.edu.ORCID http://orcid.org/0000-0002-3894-685X
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2014 to 2023
$26.0MToward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AHMED, RAFI · 2012 to 2022
$17.6MProject 3: T CellsU54CA260517 · NCI · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2020 to 2024
$10.4MClinical and translational evaluation of vector saliva based vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseasesZIAAI001221 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MEMOLI, MATTHEW · 2017 to 2023
$5.8MEffects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohortR01AI130398 · NIAID · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2017 to 2021
$4.0MSARS-CoV-2 PathogenesisZIAAI001271 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TAUBENBERGER, JEFFERY · 2020 to 2025
$3.1MRegulation of the IgG Fc domain repertoireR01AI139119 · NIAID · STANFORD UNIVERSITY · PI WANG, TAIA · 2019 to 2023
$2.8MFUNCTIONAL ANALYSIS OF PATHOGENIC AND PROTECTIVE PEANUT ALLERGEN-SPECIFIC HUMAN ANTIBODIESR01AI125567 · NIAID · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2017 to 2022
$2.6MStorage and recall of human B cell memory of influenza over tissues and timeR01AI127877 · NIAID · STANFORD UNIVERSITY · PI BOYD, SCOTT DEXTER · 2017 to 2021
$2.0MNCATS NIH HHS UL1 TR001866NCI NIH HHS U54 CA260517NIAID NIH HHS P01 AI097092NIAID NIH HHS R01 AI125567NIAID NIH HHS R01 AI127877NIAID NIH HHS R01 AI130398NIAID NIH HHS R01 AI139119NIAID NIH HHS T32 AI007290NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI111825U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI139119U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI111825U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U54CA260517
Abstract
Severe acute respiratory syndrome coronavirus 2 infections can cause coronavirus disease 2019 (COVID-19), which manifests with a range of severities from mild illness to life-threatening pneumonia and multi-organ failure. Severe COVID-19 is characterized by an inflammatory signature, including high levels of inflammatory cytokines, alveolar inflammatory infiltrates and vascular microthrombi. Here we show that patients with severe COVID-19 produced a unique serologic signature, including an increased likelihood of IgG1 with afucosylated Fc glycans. This Fc modification on severe acute respiratory syndrome coronavirus 2 IgGs enhanced interactions with the activating Fcγ receptor FcγRIIIa; when incorporated into immune complexes, Fc afucosylation enhanced production of inflammatory cytokines by monocytes, including interleukin-6 and tumor necrosis factor. These results show that disease severity in COVID-19 correlates with the presence of proinflammatory IgG Fc structures, including afucosylated IgG1.
Indexed as
AdolescentAdultAgedChildCOVID-19CytokinesFemaleGlycosylationHumansImmunoglobulin GInterleukin-6MaleMiddle AgedReceptors, IgGSARS-CoV-2Severity of Illness IndexCytokinesFCGR3A protein, humanImmunoglobulin GInterleukin-6Receptors, IgGTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.